The estimated Net Worth of Daniel Faga is at least $47.9 million dollars as of 22 March 2024. Mr. Faga owns over 148,940 units of Mirati Therapeutics Inc stock worth over $43,971,407 and over the last 9 years he sold MRTX stock worth over $3,957,741. In addition, he makes $0 as Chief Operating Officer et Executive Vice President at Mirati Therapeutics Inc.
Daniel has made over 12 trades of the Mirati Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 148,940 units of MRTX stock worth $3,389,874 on 22 March 2024.
The largest trade he's ever made was selling 148,940 units of Mirati Therapeutics Inc stock on 22 March 2024 worth over $3,389,874. On average, Daniel trades about 11,673 units every 96 days since 2016. As of 22 March 2024 he still owns at least 749,087 units of Mirati Therapeutics Inc stock.
You can see the complete history of Mr. Faga stock trades at the bottom of the page.
Daniel R. Faga serves as Chief Operating Officer, Executive Vice President of the Company. He has served as our Executive Vice President and Chief Operating Officer since January 2020. Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for the Corporate Strategy & Public Affairs organization including leadership of corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.
Daniel Faga is 40, he's been the Chief Operating Officer et Executive Vice President of Mirati Therapeutics Inc since 2020. There are 19 older and no younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... et Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: